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ABSTRACT
Objectives: We investigated the efficacy, side effects, and prognostic factors of concurrent chemoradiotherapy for patients 
with stage Ib3-IIa2 cervical cancer.
Material and methods: We conducted a retrospective analysis of clinicopathologic data from 73 patients with stage 
Ib3-IIa2 cervical cancer who received concurrent chemoradiotherapy from January 2008 to December 2013 in our hospital. 
Overall response and disease control rates were used to evaluate short-term outcomes; the 3-year and 5-year disease-free 
survival and overall survival were used to evaluate long-term efficacy. Toxicity reactions and prognostic factors were recorded.
Results: With concurrent chemoradiotherapy, overall response and disease control rates were 91.78% and 97.26%, respectively. 
The 3-year disease-free and overall survival were 80.82% and 83.56%; the 5-year disease-free and overall survival were 75.34% 
and 79.45%, respectively. All side effects were tolerated and potentially alleviated by symptomatic treatment. Tumor pathological 
type, differentiated degree, primary tumor size and squamous cell carcinoma antigen levels before and after treatment were 
closely related to survival (univariate analysis; p < 0.05). Pathological type, primary tumor size and squamous cell carcinoma 
antigen levels one month after treatment were independent prognostic factors for long-term outcome (multivariate analysis).
Conclusions: Short- and long-term efficacy of concurrent chemoradiotherapy for stage Ib3-IIa2 cervical cancer is well-de-
termined and tolerable. Patients with adenocarcinomas, tumor diameter ≥ 5 cm and squamous cell carcinoma antigen 
levels ≥ 1.5 ng/mL (one month after treatment) had poor prognosis and should be assessed further.
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INTRODUCTION
Patients with stage Ib3 and IIa2 cervical cancer have 
a poorer prognosis because of the larger tumour volume and 
difficult control of the local lesions. The 5-year survival rate of 
patients was reported to be approximately 50%–60% [1, 2]. 
At present, there is no uniform standard therapy mentioned 
in the NCCN guidelines (2019). The options include pelvic 
external irradiation + cisplatin (concurrent chemothera-
py) + vaginal brachytherapy (level 1 evidence); extensive 
hysterectomy + pelvic lymphadenectomy ± para-abdominal 
aortic lymph node sampling (level 2B evidence); and post-ra-
diotherapy + assisted hysterectomy (level 3 evidence) [3]. 
However, the best treatment is controversial. We reviewed 
the clinical data of 73 patients with stage Ib3 and IIa2 cervi-
cal cancer treated with concurrent chemoradiotherapy at 
our hospital and evaluated the short-term and long-term 
efficacies and influencing factors associated with chemora-
diotherapy in order to provide evidence for guiding clinical 
treatment.
Objectives
To explore the efficacy and adverse reactions of concur-
rent chemoradiotherapy for stage Ib3 and IIa2 cervical can-
cer and to discuss the related factors affecting prognosis, so 
as to provide reference for the follow-up clinical treatment.
MATERIAL AND METHODS
General information
The clinical and pathological data of 73 patients with 
stage Ib3 and IIa2 cervical cancer who received concurrent 
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chemoradiotherapy in the Gynecological Oncology Depart-
ment of our hospital (Beijing Obstetrics and Gynecology 
Hospital, Capital Medical University, Beijing, China.) from 
January 2008 to December 2013 were collected. The entry 
criteria consisted of the following: 1. Cervical squamous 
cell carcinoma or adenocarcinoma confirmed by pathol-
ogy; 2. 2018 International Federation of Gynaecology and 
Obstetrics (FIGO) stage Ib3 or IIa2 confirmed by at least two 
doctors at a level of deputy director of gynaecological on-
cology or above; 3.patients initially treated with concurrent 
chemoradiotherapy;4. no serious heart, liver, kidney, brain 
or hematopoietic system diseases; no history of immune-re-
lated diseases; and no other tumours. 5. The clinical data 
are complete. Exclusion criteria: 1. Complicated with other 
tumours; 2. Cervical cancer of other pathological types, such 
as adenosquamous carcinoma, clear cell carcinoma; 3. His-
tory of previous radiotherapy or chemotherapy; 4. Refusal to 
participate in the study. General information for the patients 
is shown in Table 1.
Therapy
All patients were treated with concurrent chemoradio-
therapy. Radiotherapy consisted of external beam radio-
therapy and intracavitary radiotherapy. The external beam 
radiotherapy was performed with a Cobalt-60 machine. The 
prescription of external beam radiotherapy for whole pelvic 
was 50 Gy/2.0 Gy/25 f. When the external radiation dose 
reaches 20–30 Gy, the intracavitary radiotherapy started. 
Intracavitary radiotherapy was performed with a 192-Iridium 
(Ir) post-installed machine, 6–7 times at point A, for a total of 
36–42 Gy. Concurrent chemotherapy was given during the 
radiotherapy period. The chemotherapy regimen was either 
a single cisplatin intravenous infusion (40 mg/m2) once 
a week for five–six cycles or 5-fluorouracil (5-FU; 3–4 g/m2, 
96-hour continuous intravenous pump infusion) + cisplatin 
(20 mg/m2, 1–4 days), once every four weeks for two–three 
cycles.
Efficacy and adverse reactions
All patients underwent gynaecological examinations, 
pelvic and abdominal computed tomography (CT) scans or 
magnetic resonance imaging (MRI), and chest X-ray imaging 
before and after treatment. The curative effect of treatment 
was evaluated accordingly. The adverse reactions of all pa-
tients were recorded during chemoradiotherapy and during 
the follow up period, including gastrointestinal reactions, 
nephrotoxicity and urinary system reactions, and bone mar-
row suppression. These adverse reactions were assessed 
by World Health Organization (WHO) criteria for acute and 
subacute toxicities [4].
Follow-up began at the end of treatment and con-
tinued until December 31, 2018. Patients were followed 
every 3 months for 2 years and every 6 months thereafter. 
Follow-up assessments included a gynecological exami-
nation, a ThinPrep cytologic test (TCT), blood squamous 
cell carcinoma antigen (SCC-Ag) levels, basin abdominal 
computed tomography (CT) or magnetic resonance imag-
ing (MRI), and chest X-ray imaging. If no abnormality was 
observed, TCT was checked once a year, and CT/MRI and 
X-ray images were checked every six months.
During the follow-up period patients were evaluated 
according to the Response Evaluation Criteria in Solid Tu-
mors (RECIST) criteria. The RECIST criteria comprises four 
categories: complete remission (CR), partial remission (PR), 
disease progression (PD), and disease stability (SD).
Short-term efficacy was evaluated by CR + PR and dis-
ease control rate (CR + PR + SD) three months after treat-
ment and long-term efficacy was evaluated by the 3-year 
and 5-year disease-free survival (DFS) and overall survival 
(OS) rates.
Criteria
We defined the survival time as the period from the 
beginning of treatment to the last follow-up or death. 
Tumor-free survival time was defined as the time of recur-
Table 1. Univariate analysis of prognostic factos
Factors N [%] 5-year survival rate p value
Age [year]
≤ 40 21 (28.77) 76.3% 0.709
> 40 52 (71.23) 80.8%
Pathological Type
Squamous 63 (86.30) 82.5% 0.034
Adenocarcinoma 10 (13.70) 60.0%
Stages
Ib3 50 (68.49) 80.0% 0.137
IIa2 23 (31.51) 78.3%
Differentiation
G1 6 (8.22) 83.3% 0.046
G2 53 (72.60) 81.1%
G3 14 (19.18) 71.4%
Diameter
< 5 cm 61 (83.56) 83.6% 0.032
≥ 5 cm 12 (16.44) 58.3%
SCCA* before treatment
≥ 1.5 ng/mL 49 (67.12) 77.6% 0.038
< 1.5 ng/mL 24 (32.88) 83.3%
SCCA after treatment (1 month)
≥ 1.5 ng/mL 13 (17.81) 53.8% 0.012
< 1.5 ng/mL 60 (82.19) 85.0%
SCCA — squamous cell carcinoma antigen
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rence, metastasis, or last follow-up from the beginning of 
treatment of any site.
Statistical analysis
The experimental data are presented as mean ± stand-
ard deviation (SD). Kaplan-Meier method was used for sur-
vival analysis. The chi-square test was used for univariate 
analysis and logistic regression was used for multivariate 
analysis. p-values < 0.05 were considered statistically sig-
nificant. Calculations were carried out using the Statistical 
Package for the Social Sciences (SPSS for Windows, version 
19.0, SPSS Inc., Chicago, IL, USA).
RESULTS
Short-term and long-term efficacies
The average follow-up time was 68.9 months. The 3-year 
follow-up rate was 98.63%, and the 5-year follow-up rate 
was 97.26%. During the follow-up period, 18 of 73 patients 
relapsed (24.66%); 15 died (20.54%) after relapse, and 3 sur-
vived with tumours (4.11%). Three months after the end of 
treatment there were 60 cases of CR, 7 cases of PR, 4 cases 
of SD, and 2 cases with PD. The effective rate (CR + PR) was 
91.78%, and the disease control rate (CR + PR + SD) was 
97.26%. The 3-year DFS rate was 80.82%, and the total sur-
vival rate was 83.56%. The 5-year DFS rate was 75.34% and 
the total survival rate was 79.45%.
Adverse effects
The incidence of chemotherapy-related gastrointestinal 
reactions, bone marrow suppression, and nephrotoxicity 
were 56.16% (41/73), 58.90% (43/73), and 5.48% (4/73), 
respectively, all of which were grades I–II. The incidence of 
radiation-related proctitis and cystitis was 21.92% (16/73) 
and 19.18% (14/73), respectively. All adverse reactions were 
tolerated and remitted after symptomatic treatment. The 
therapy was completed as planned.
Prognostic factors
Multivariate analysis showed that pathological type, 
primary tumor size and SCC-Ag levels one month after treat-
ment were independent factors affecting long-term efficacy 
(p < 0.05; Tab. 2). The respective survival curves are shown 
in Figure 1–3.
DISCUSSION
According to the FIGO classification, locally advanced 
cervical cancer broadly refers to Ib3-IVa tumors and more 
Table 2. Multivariate analysis of prognostic factos
Factors β p OR 95% CI
Pathological type 0.191 0.023 1.958 1.473–3.166
Diameter 0.096 0.040 1.716 1.304–2.316
SCCA after treatment 
(1 month) 0.087 0.030 1.804 1.286–2.805
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Figure 1. Survival curves of different pathological types of cervical 
cancer
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Figure 2. Survival curves of different tumor diameters
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Figure 3. Survival Curves of Different SCCA Values after treatment  
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specifically to Ib3 and IIa2 tumors. Locally advanced cervical 
cancers have a tumor diameter larger than 4 cm. Surgery 
is often difficult in patients with locally advanced cervi-
cal cancer, and there are many pathological high-risk fac-
tors after surgery that can increase the risk for recurrence 
and metastasis [5]. At present, commonly used treatment 
methods are neoadjuvant chemotherapy plus surgery, 
post-radiotherapy supplementary surgery, and concurrent 
chemoradiotherapy [6].
Previous studies have shown that concurrent chemora-
diotherapy can enhance the sensitivity of patients to radio-
therapy [7], improve the 5-year survival rate, and increase 
the local control rate of tumors [8]. The mechanism may be 
as follows: 1. Chemotherapy is a systemic therapy, which 
can kill distant metastasis and local tumor cells, weaken the 
invasiveness of tumor; 2. Chemotherapy prevents the cell 
damage and repair caused by radiotherapy; 3. Chemother-
apy and radiotherapy act on different phases of cell cycle 
and complement each other, but do not prolong the overall 
treatment time; 4. Chemotherapy can reduce the propor-
tion of hypoxic cells and increase the effect of tumor cells 
on radiotherapy Sensitivity. Five randomized clinical trials 
of concurrent chemoradiotherapy for stage Ib–IVa cervical 
cancer reported in the United States in 1999 showed that 
current chemoradiotherapy reduced the risk of death by 
30–50% compared with radiotherapy alone. Datta et al. [9] 
analyzed the curative effect of radical concurrent chemo-
radiotherapy, radical concurrent radiotherapy, and postop-
erative concurrent radiotherapy and chemotherapy in the 
treatment of Ib2 and IIa2 cervical cancer, and found that 
the curative effect of concurrent chemoradiotherapy was 
better than the other two groups. Currently, the National 
Cancer Institute recommends platinum-based concurrent 
chemoradiotherapy as the standard treatment for locally 
advanced cervical cancer [10]. Cisplatin is one of the most 
sensitive chemotherapeutic drugs [11]. The NCCN Guide-
lines® for cervical cancer in the United States in 2019 also 
recommend that the treatment of stage Ib3 and IIa2 cervical 
cancer should be the combination of pelvic radiotherapy, 
brachytherapy, and cisplatin-containing concurrent chemo-
therapy, which is the level-1 evidence.
The current study results showed that the effective rate 
of radical concurrent radiotherapy and chemotherapy was 
91.78%. The 3-year survival rate was 83.56%, and the 5-year 
survival rate was 79.45%, which was similar to previous 
studies. Our results indicated that concurrent chemora-
diotherapy was effective in the treatment of stage Ib3 and 
stage IIa2 cervical cancer.
Although chemoradiotherapy acts on tumor cells and 
coordinates and improves the therapeutic effect, it is not 
without adverse effects. The main reported adverse effects 
were radiation enteritis, radiation cystitis, digestive tract 
reactions, bone marrow suppression, and damage to liver 
and kidney functions [12]. Compared with concurrent ra-
diotherapy and chemotherapy, neoadjuvant chemotherapy 
plus surgery and post-operative supplementary radiother-
apy have different complications. Fabri [13] has reported 
no difference in adverse reactions between neoadjuvant 
chemotherapy and concurrent chemoradiotherapy. Dang 
et al. [14] compared the complications of concurrent radio-
therapy and chemotherapy with that of radiotherapy alone 
and found that concurrent radiotherapy and cisplatin-based 
chemotherapy could increase the therapeutic effect in cervi-
cal cancer patients and significantly improve the therapeutic 
benefit without increasing adverse reactions.
Like the above studies, the current study showed that the 
adverse events related to chemotherapy were all grades I–II. 
The incidences of radiation-related proctitis and cystitis 
were 21.92% and 19.18%, respectively, which were tolerable.
However, concurrent chemoradiotherapy still face 
many problems: 1. The lymph node metastasis rate of lo-
cal advanced cervical cancer is high, concurrent chemora-
diotherapy can not accurately evaluate whether the lymph 
node metastasis or the location of metastasis, so it’s difficult 
to determine the radiotherapy field; 2. For young patients, 
they are faced with the problem of ovarian function loss; 
3. In addition to radiation cystitis, radiation enteritis and 
other radiotherapy specific adverse reactions, there are also 
literature reports that the long-term adverse reaction rate of 
concurrent chemoradiotherapy is higher than that of radio-
therapy alone, especially myelosuppression and digestive 
tract reaction, which seriously affects the quality of life of 
patients [15]; 4. In some developing countries, radiotherapy 
equipment and afterloading equipment are insufficient; 
5. The survival rate of concurrent chemoradiotherapy for 
local advanced cervical cancer is still not ideal. All above 
these questions require further observation and research.
At present, there are few reports on the prognostic 
factors of Ib3 and IIa2 cervical cancer treated with radical 
concurrent chemoradiotherapy. Kim [16] analyzed the clini-
cal data of 174 patients with stage Ib1-IVa cervical cancer 
who received radical concurrent chemoradiotherapy. Stage, 
size, and clinical response had significant effects on OS. PFS 
was also affected by the level of SCC-Ag after treatment. 
Patients with normal SCC-Ag levels had a longer DFS after 
treatment. Chen [7] performed a multivariate analysis of 
125 patients with stage Ib2-III cervical cancer who received 
intensity-modulated radiation therapy combined with con-
current chemotherapy. Chen showed that cervical adeno-
carcinoma and lymph node metastasis were independent 
adverse prognostic factors for locally advanced cervical 
cancer. Endo [17] found that tumor diameter > 6 cm, lymph 
node enlargement, and distant metastasis were significantly 
and independently associated with adverse outcomes in 
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patients undergoing radical concurrent chemoradiotherapy. 
Queiroz [18] showed that in stage Ib and IIa cervical can-
cer, there was a poor prognosis for patients with lymph 
node metastasis and SCC-Ag levels that did not decrease 
to 1.5 mg/L one month after treatment.
Our study results supported findings of previous studies 
in terms of the relationship of survival rate to pathological 
type, differentiation degree, primary tumor size and SCC-Ag 
value of blood before and after treatment. Limitations of our 
study include the retrospective design and small number of 
cases. Prospective studies that include larger patient cohorts 
are needed for further research.
CONCLUSIONS
In conclusion, we analyzed the efficacy and adverse 
reactions of concurrent chemoradiotherapy for Ib3 and 
IIa2 cervical cancer and discussed the related factors af-
fecting prognosis. Our findings indicate that concurrent 
chemoradiotherapy is an effective and tolerable treatment 
for this cancer. We should pay more attention to patients 
with adenocarcinoma, tumor diameter ≥ 5 cm and blood 
SCC-Ag levels ≥ 1.5 ng/mL one month after treatment and 
explore a more adequate treatment plan in order to improve 
the survival rate. A multi-center, large-sample prospective 
study is required to further confirm the validity of our con-
clusions.
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